Univariate and multivariate analyses of risk factors for cytomegalovirus disease
| Risk factor . | Days 0-100 . | Days 101-365 . | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate RR (95% CI) . | P . | Adjusted RR (95% CI) . | P . | Univariate RR (95% CI) . | P . | Adjusted RR (95% CI) . | P . | |
| Nonmyeloablative vs myeloablative HSCT | 0.27 (0.06-1.18) | .04 | 0.16 (0.04-0.76) | .01 | 2.19 (0.67-7.17) | .20 | 3.86 (1.16-12.89) | .03 |
| TBI > 2 Gy vs no TBI | 0.95 (0.32-2.82) | NS | 1.38 (0.23-8.24) | NS | ||||
| TBI 2 Gy vs no TBI | 0.38 (0.08-1.87) | .20 | 1.87 (0.31-11.17) | NS | ||||
| TBI 2 Gy + fludarabine vs no TBI | 0.003-150 | .04 | 4.38 (0.73-26.27) | .10 | ||||
| MMF vs other | 0.38 (0.11-1.35) | .10 | 2.75 (0.81-9.41) | .10 | ||||
| PBSCs vs BM | 0.56 (0.07-4.24) | NS | ∞3-150 | NS | ||||
| Matched unrelated vs matched related | 0.90 (0.12-6.87) | NS | 3.90 (0.84-18.21) | .13 | ||||
| Poor vs good diagnosis group | 1.45 (0.52-4.07) | NS | 3.01 (1.04-8.71) | .04 | 1.23 (0.38-4.04) | NS | ||
| Age, older than 40 y vs other | 0.91 (0.26-3.24) | NS | 1.05 (0.23-4.86) | NS | ||||
| CMV, high risk vs other | ∞3-150 | < .001 | ∞3-150 | < .001 | 7.70 (0.99-60.17) | .01 | ||
| aGVHD, higher than grade 1 vs grades 0-1 | 4.63 (0.89-24.04) | .04 | ∞3-150 | .01 | ||||
| CMV antigenemia vs no antigenemia | 2.61 (0.79-8.60) | .12 | ||||||
| CMV antigenemia during first 100 days vs no antigenemia | 12.99 (1.66-101.46) | .001 | 18.31 (2.30-146.06) | < .001 | ||||
| Risk factor . | Days 0-100 . | Days 101-365 . | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate RR (95% CI) . | P . | Adjusted RR (95% CI) . | P . | Univariate RR (95% CI) . | P . | Adjusted RR (95% CI) . | P . | |
| Nonmyeloablative vs myeloablative HSCT | 0.27 (0.06-1.18) | .04 | 0.16 (0.04-0.76) | .01 | 2.19 (0.67-7.17) | .20 | 3.86 (1.16-12.89) | .03 |
| TBI > 2 Gy vs no TBI | 0.95 (0.32-2.82) | NS | 1.38 (0.23-8.24) | NS | ||||
| TBI 2 Gy vs no TBI | 0.38 (0.08-1.87) | .20 | 1.87 (0.31-11.17) | NS | ||||
| TBI 2 Gy + fludarabine vs no TBI | 0.003-150 | .04 | 4.38 (0.73-26.27) | .10 | ||||
| MMF vs other | 0.38 (0.11-1.35) | .10 | 2.75 (0.81-9.41) | .10 | ||||
| PBSCs vs BM | 0.56 (0.07-4.24) | NS | ∞3-150 | NS | ||||
| Matched unrelated vs matched related | 0.90 (0.12-6.87) | NS | 3.90 (0.84-18.21) | .13 | ||||
| Poor vs good diagnosis group | 1.45 (0.52-4.07) | NS | 3.01 (1.04-8.71) | .04 | 1.23 (0.38-4.04) | NS | ||
| Age, older than 40 y vs other | 0.91 (0.26-3.24) | NS | 1.05 (0.23-4.86) | NS | ||||
| CMV, high risk vs other | ∞3-150 | < .001 | ∞3-150 | < .001 | 7.70 (0.99-60.17) | .01 | ||
| aGVHD, higher than grade 1 vs grades 0-1 | 4.63 (0.89-24.04) | .04 | ∞3-150 | .01 | ||||
| CMV antigenemia vs no antigenemia | 2.61 (0.79-8.60) | .12 | ||||||
| CMV antigenemia during first 100 days vs no antigenemia | 12.99 (1.66-101.46) | .001 | 18.31 (2.30-146.06) | < .001 | ||||
RR indicates relative risk; CI, confidence interval; HSCT, hematopoietic stem cell transplantation; aGVHD, acute GVHD; and NS, not significant. For other abbreviations, see Table 1.
If all CMV disease events occurred in patients who composed all or none of a risk factor category, then no confidence interval could be calculated, and the relative risk was infinite (∞) or zero, respectively.